Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.39 |
| ▸ | OGA | O60502 | 1/20 | 0.37 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | BPTF | Q12830 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20249268 | 0.84 | HRH4 (0.51) | HRH4CYP1A2KDM4E | |
| SCHEMBL16133059 | 0.84 | CYP1A2 (0.52) | CYP1A2 | |
| SCHEMBL20249360 | 0.83 | TRPV1 (0.43) | TRPV1HRH4KDM4ELMNAHSD17B10 | |
| SCHEMBL24622064 | 0.82 | KDM2B (0.41) | — | |
| SCHEMBL20249325 | 0.80 | HRH3 (0.48) | TRPV1OGAHRH4KDM4ELMNA | |
| SCHEMBL18291262 | 0.79 | CYP1A2 (0.36) | TRPV1HRH4CYP1A2LMNABPTF | |
| SCHEMBL15874637 | 0.79 | CYP1A2 (0.61) | TRPV1CYP1A2LMNABPTF | |
| SCHEMBL16430192 | 0.79 | OGA (0.45) | TRPV1OGAHRH4CYP1A2KDM4E | |
| SCHEMBL20249130 | 0.79 | ALDH1A1 (0.51) | KDM4ELMNAHSD17B10 | |
| SCHEMBL20249099 | 0.79 | BPTF (0.57) | HRH4CYP1A2KDM4EHSD17B10BPTF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TEIJIN PHARMA LIMITED (JP) | 2018-06-14 | — | — | US | disclosed |
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TEIJIN PHARMA LIMITED (JP) | 2018-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | CDK4, CDK6, CDK16 | TRPV1 3672/4885OGA 4627/4885HRH4 1763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.